Following up h e finQng that the non-imidazole drug clozapine shows a considerable histamine H3 receptor antagonistic activiryl 1.21 , a scrim of analogues and metabolites (clorapinc-N-oxide. and N-desmcthylclozapine) were tested for thcir affinity towards thc H3 receptor using the radiolabelled H,
Effects of lithium on [3H](–)quinuclidinyl benzilate ([3H](–)QNB) binding to rat brain muscarinic cholinergic receptors
✍ Scribed by R. E. Hruska; L. M. Ludmer; A. Pert; W. E. Bunney Jr.
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- English
- Weight
- 430 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0360-4012
No coin nor oath required. For personal study only.
✦ Synopsis
Addition of lithium in vitro inhibited the binding of 3HQNB to muscarinic cholinergic receptors of homogenates of tissue prepared from the striatum, cortex, and hippocampus of rat brain. Chronic in vivo exposure of rats to lithium in their food produced serum levels of lithium comparable to therapeutic levels. After in vivo exposure, the tissue homogenates prepared from these rats had an apparent decrease in receptor density in the three brain areas. However, if the tissue homogenates were washed twice, before addition to the assays, no differences in binding were detectable. Similar effects on unwashed and washed tissue homogenates can be demonstrated after in vivo exposure to lithium. Therefore, the apparent decrease in binding after in vivo lithium treatment is probably due to lithium retained in the tissue. No permanent alterations in the muscarinic receptor characteristics were measurable after the removal of the lithium. Nevertheless, in vivo interactions at muscarinic receptors may be important under conditions when therapeutic levels of lithium are present.
📜 SIMILAR VOLUMES
Effect of 3-PPP, a putative dopamine autoreceptor agonist, on [3H]ligand binding to dopamine receptors of calf and rat striatum. Drug Dev. Res. 3:177-184, 1983. 3-(3-Hydroxyphenyl)-N-n-propyliperidine (3-PPP) is most effective in inhibiting I3HJapomorphine binding in rat striatal membranes, with Ki
## thio-2-propyl]-2-chloroadenosine (NNC 21-0136) is a novel adenosine agonist with neuroprotectant properties in rodent models of focal and global ischemia that exhibits diminished cardiovascular side effects when compared to reference A 1 agonists [Sheardown et al., 1995]. NNC 21-0136 is shown t
## Abstract The effect of phospholipases and proteases on the membrane‐bound and solubilized A~1~ adenosine receptor has been studied. Phospholipids modulate the [^3^H]N^6^‐(R)‐phenylisopropyladenosine binding to A~1~ adenosine receptors in crude membranes and in soluble preparations, because chang